No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LUCD Lucid Diagnostics
- 0.789
- +0.038+5.02%
Close Jul 5 16:00 ET
- 0.760
- -0.029-3.64%
Post 16:33 ET
41.36MMarket Cap-626P/E (TTM)
0.817High0.750Low76.15KVolume0.800Open0.751Pre Close59.75KTurnover0.44%Turnover RatioLossP/E (Static)52.42MShares1.72152wk High-1.28P/B13.66MFloat Cap0.63052wk Low--Dividend TTM17.31MShs Float13.520Historical High--Div YieldTTM8.85%Amplitude0.630Historical Low0.784Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
Express News | Lucid Diagnostics Announces Data From ESOGUARD BE-1 Study; Demonstrates 87.5% Sensitivity And 98.6% NPV For EsoGuard Test; Strengthens Clinical Validity For Medicare LCD Pre-Submission And Commercial Payor Engagements; Cleveland VA Study Data Accepted...
Express News | Lucid Diagnostics Announces Positive Data From Its Esoguard Be-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard® Esophageal Precancer Testing in a Screening Population
Express News | Lucid Diagnostics Inc Files for Offering of up to 72.4 Mln Shares by the Selling Stockholders - SEC Filing
Express News | Lucid Diagnostics Inc -Received Notice From Nasdaq, Notified Failure to Satisfy a Continued Listing Rule or Standard by Co's Common Stock
Express News | 4,000TH Firefighter Undergoes Lucid Diagnostics' Esoguard® Esophageal Precancer Testing
Comments
$Lucid Diagnostics(LUCD.US$ Reuters · 1 min ago Lucid Diagnostics Announces Positive Data From Its Esoguard Be-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard® Esophageal Precancer Testing in a Screening Population
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago
PR Newswire· 2 mins ago
1
2
$Lucid Diagnostics(LUCD.US$
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
2
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg